Drugs / HDM2020
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07638891 | Apr 2026 → Jan 2027 expected | non-small cell squamous lung carcinoma | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07098052 | Aug 2025 → Sep 2026 overdue | cancer | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HDM2020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07638891 ↗ |
| Modality | Other / unclassified | “HDM2020 (FGFR2b-ADC)” NCT07638891 ↗ |
| Route | Intravenous | “HDM2020 Intravenous administration” NCT07638891 ↗ |